scorecardresearch

FabiFlu: Glenmark launches Covid drug at Rs 103 per tablet

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19, it said in a statement.

Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet. The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19, it said in a statement. The tablets are being produced by the company at its Baddi facility in Himachal Pradesh. The drug will be available both through hospitals and the retail channel, Glenmark said.

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

Most Read In Lifestyle